Targeting COX-2 with selective COX-2 inhibitors (NS-398, SC-236 and celecoxib) has proven effective to reduce human glioblastoma cell viability in vitro [4,6-9] and in rodent models [6,9-11]. Here, PTGS2 is linked to glioblastoma.